Current Treatment for Benign Prostatic Hyperplasia.
作者信息
Miernik Arkadiusz, Gratzke Christian
机构信息
Department of Urology at University Hospital Freiburg.
出版信息
Dtsch Arztebl Int. 2020 Dec 4;117(49):843-854. doi: 10.3238/arztebl.2020.0843.
BACKGROUND
Benign prostatic hyperplasia (BPH) is characterized by the occurrence of.disorders of urine storage and bladder emptying. Most men over the age of 60 years are affected to some degree.
METHODS
A selective literature search with additional scrutiny of guidelines and meta-analyses.
RESULTS
The management of patients with BPH is complex. Emptying and retention disorders can be treated by various pharmacological and surgical means. Transurethral resection of the prostate (TURP) has long been considered the gold standard for operative treatment. Transurethral enucleation procedures show a better risk profile in some uses, however, and have, above all, largely displaced suprapubic prostatectomy. Numerous innovative treatment options have been developed in recent years, but their long-term effects remain to be determined. These treatment techniques can nevertheless be used in individual cases after thorough discussion with the patient.
CONCLUSION
The care of patients with BPH should be interdisciplinary. The efficacy and safety of many new developments in the area of pharmacological and minimally invasive treatment remain to be demonstrated in randomized trials.
相似文献
Dtsch Arztebl Int. 2020-12-4
Urologe A. 2010-1
Minerva Urol Nefrol. 2009-9
Urologe A. 2019-4
引用本文的文献
Int Urol Nephrol. 2025-7-14
本文引用的文献
Cochrane Database Syst Rev. 2019-12-3
Prostate Cancer Prostatic Dis. 2019-2-28